Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012, with the announcement issued on May 10, 2012. The filing serves as a report of a material corporate event rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for GSK. The document focuses exclusively on the terms of a proposed acquisition.
- Acquisition Target: Human Genome Sciences (NASDAQ: HGSI)
- Offer Price: US $13.00 per share in cash
- Premium: 81% over the closing share price of US $7.17 on April 18, 2012
Material Changes
The primary material change is the commencement of a tender offer to acquire all outstanding shares of Human Genome Sciences. This represents a significant strategic shift involving a potential business combination.
Guidance, Outlook, and Risks
Transaction Timeline: The tender offer and withdrawal rights are scheduled to expire at 12:00 midnight New York City time on June 7, 2012, unless extended.
Conditions: Closing is subject to terms and conditions detailed in the offer document.
Advisors: Lazard and Morgan Stanley are acting as financial advisors; Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz are providing legal advice.
Risks and Forward-Looking Statements: The filing includes a cautionary statement that actual results may differ materially from forward-looking statements regarding the benefits of the transaction, future financial results, and GSK's plans. Investors are directed to the "Risk factors" section of the 2011 Annual Report (Form 20-F) for a detailed description of factors affecting operations.
Investor Verification Checklist
- Verify the final terms and conditions in the official Offer to Purchase document filed with the SEC.
- Confirm the expiration date of the tender offer (June 7, 2012) and any potential extensions.
- Review the "Risk factors" in GSK's 2011 Annual Report on Form 20-F for operational risks.
- Monitor regulatory approvals required for the acquisition of Human Genome Sciences.